NASDAQ: ATNF180 Life Sciences Corp Stock
$1.81-0.19 (-9.5%)
Updated Sep 13, 2024
ATNF Price
$1.81
Fair Value Price
$1.73
Market Cap
$1.75M
52 Week Low
$1.31
52 Week High
$15.72
P/E
-0.11x
P/B
-4.2x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.55M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-10.36
Operating Cash Flow
-$4M
Beta
0.51
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ATNF Overview
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATNF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATNF ($1.81) is overvalued by 4.64% relative to our estimate of its Fair Value price of $1.73 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATNF ($1.81) is not significantly undervalued (4.64%) relative to our estimate of its Fair Value price of $1.73 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATNF is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATNF due diligence checks available for Premium users.
Be the first to know about important ATNF news, forecast changes, insider trades & much more!
ATNF News
Valuation
ATNF fair value
Fair Value of ATNF stock based on Discounted Cash Flow (DCF)
Price
$1.81
Fair Value
$1.73
Overvalued by
4.64%
ATNF ($1.81) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATNF ($1.81) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATNF is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATNF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
-245.33x
Market
23.21x
ATNF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.2x
Industry
6.54x
ATNF's financial health
Profit margin
Revenue
$0.0
Net Income
$11.8k
Profit Margin
0%
ATNF's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.9M
Liabilities
$4.3M
Debt to equity
-10.36
ATNF's short-term liabilities ($4.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATNF's short-term assets ($2.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATNF's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATNF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$727.2k
Investing
$0.0
Financing
-$264.9k
ATNF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATNF vs Biotech Stocks
180 Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.